Enrichment designs

Clinical Trials in Neurology: Design, Conduct, Analysis

Volumn , Issue , 2012, Pages 127-134

  Kellogg, Kathryn M ^a   Markman, John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925089676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139032445.013     Document Type: Chapter

References (29)

1. Amery W and Dony J. A clinical trial design avoiding undue placebo treatment. J ClinPharmacol1975; 15: 674–9.
2. Chow SC LJ. Design and Analysis of Clinical Trials, 2nd ed. Hoboken, NJ:John Wiley & Sons, Inc, 2004.
3. Quessy SN. Two-stage enriched enrolment pain trials: a brief review of designs and opportunities for broader application. Pain 2010; 148: 8–13.
4. Straube S DS, Derry S, McQuay HJ and Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review.Br J Clin Pharmacol 2008; 66: 266–75.
5. McQuay HJ, Derry S, Moore RA, et al. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008; 135: 217–20.
6. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology.Clin J Pain 2009; 25: 797–807.
7. Quitkin FM and Rabkin JG. Methodological problems in studies of depressive disorder: utility of the discontinuation design. J Clin Psychopharm 1981; 1: 282–8.
8. Kopec JA, Abrahamowicz M and Esdaile JM. Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 1993; 46: 959–71.
9. Ho TW BJ, Froman S and Polydekis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009; 141: 19–24.
10. Hewitt DJ, Ho TW, Galer B, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain2011; 152: 514–21.
11. Fu P, Dowlati A and Schluchter M. Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.J Clin Oncol 2009; 27: 4135–41.
12. Byas-Smith MG, Max MB, Muir J and Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design. Pain 1995; 60: 267–74.
13. Knipschild P, Lef ers P and Feinstein AR. The qualfication period. J Clin Epidemiol 1991; 44: 441–4.
14. Chow SC, editor. Encyclopediaof Biopharmaceutical Statistics. New York, Marcel Dekker, 2000.
15. Echt DS Liebson PR, Mitchell LB, Peters RW, et al. Mortality and morbidity in patients receiving encainide, lecainide, or placebo.The Cardiac Arrhythmia Suppression Trial. N Engl JMed1991; 324: 781–8.
16. Chow S-C. Encyclopedia of Biopharmaceutical Statistics. New York, Marcel Dekker, 2000.
17. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? AnnIntern Med 1996; 125: 605–13.
18. Betensky RA, Louis DN and Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20: 2495–9.
19. Staud R, Price DD. Long-term trials of pregabalin and duloxetine fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008; 136: 232–4.
20. Leber PD and Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled clinical trials 1998; 19: 178–87.
21. Lynch ME, Clark AJ and Sawynok J. Intravenous adenosine alleviates neuropathic pain: a double blind.placebo controlled crossover trial using an enriched enrolment design. Pain 2003; 103: 111–7.
22. Rosner GL, Stadler W and Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20: 4478–84.
23. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253–9.
24. Lemmens HJM WD, Munera C, Eltahtawy A, et al. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemporary Clin Trials 2006; 27: 165–73.
25. Freidlin B SR. Evaluation of randomized discontinuation design. J Clin Oncol 2005; 23: 5094–8.
26. Staud R and Price DD. Role of placebo factors in clinical trials with special focus on enrichment designs. Pain 2008; 139: 479–80.
27. Moore RA, Derry S and McQuay HJ. Response to: Longterm trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors.Pain 2008; 139: 477–9; author reply 9–80.
28. Sonpavde G GM, Hutson TE and Von Hof DD. Patient selection for Phase II trials. Am J Clin Oncol 2009; 32: 216–9.
29. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a doubleblind, randomized, placebo-controlled clinical trial. Clin J Pain 2009; 25: 185–92.